Quantitative SPECT (QSPECT) at high count rates with contemporary SPECT/CT systems.
Calibration
Dead time
High count rate
Quantitative SPECT
SPECT/CT
Journal
EJNMMI physics
ISSN: 2197-7364
Titre abrégé: EJNMMI Phys
Pays: Germany
ID NLM: 101658952
Informations de publication
Date de publication:
30 Oct 2021
30 Oct 2021
Historique:
received:
26
05
2021
accepted:
14
10
2021
entrez:
31
10
2021
pubmed:
1
11
2021
medline:
1
11
2021
Statut:
epublish
Résumé
Accurate QSPECT is crucial in dosimetry-based, personalized radiopharmaceutical therapy with Using up to 14 GBq of The Siemens system had a higher calibration factor (100.0 cps/MBq) and a lower dead-time constant (0.49 μs) than those from GE (75.4-87.5 cps/MBq; 1.74 μs). Activities of up to 3.3 vs. 2.3-2.7 GBq, respectively, were quantifiable by QSPECT before the observed count rate plateaued or decreased. When used in single-detector mode, the QSPECT capability of the former system increased to 5.1 GBq, whereas that of the latter two systems remained independent of the detectors activation mode. Despite similar hardware, SPECT/CT systems' response can significantly differ at high count rate, which impacts their QSPECT capability in a post-therapeutic setting.
Sections du résumé
BACKGROUND
BACKGROUND
Accurate QSPECT is crucial in dosimetry-based, personalized radiopharmaceutical therapy with
METHODS
METHODS
Using up to 14 GBq of
RESULTS
RESULTS
The Siemens system had a higher calibration factor (100.0 cps/MBq) and a lower dead-time constant (0.49 μs) than those from GE (75.4-87.5 cps/MBq; 1.74 μs). Activities of up to 3.3 vs. 2.3-2.7 GBq, respectively, were quantifiable by QSPECT before the observed count rate plateaued or decreased. When used in single-detector mode, the QSPECT capability of the former system increased to 5.1 GBq, whereas that of the latter two systems remained independent of the detectors activation mode.
CONCLUSION
CONCLUSIONS
Despite similar hardware, SPECT/CT systems' response can significantly differ at high count rate, which impacts their QSPECT capability in a post-therapeutic setting.
Identifiants
pubmed: 34718900
doi: 10.1186/s40658-021-00421-3
pii: 10.1186/s40658-021-00421-3
pmc: PMC8557232
doi:
Types de publication
Journal Article
Langues
eng
Pagination
73Subventions
Organisme : Canadian Institutes of Health Research (CIHR)
ID : MOP-142233
Informations de copyright
© 2021. The Author(s).
Références
Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1480-1489
pubmed: 28331954
EJNMMI Phys. 2018 Oct 15;5(1):25
pubmed: 30318563
EJNMMI Phys. 2018 May 16;5(1):11
pubmed: 29766354
Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):728-742
pubmed: 30506283
EJNMMI Phys. 2020 May 15;7(1):32
pubmed: 32415492
Br J Radiol. 2018 Jan;91(1081):20160402
pubmed: 27845567
J Nucl Med. 2019 Jan;60(1):50-59
pubmed: 29976698
Phys Med Biol. 2011 Sep 7;56(17):R145-82
pubmed: 21828904
EJNMMI Phys. 2018 May 2;5(1):8
pubmed: 29717385
Phys Med Biol. 2019 Dec 19;64(24):245013
pubmed: 31766032
J Nucl Med. 1974 Jun;15(6):412-6
pubmed: 4829200
Med Phys. 2013 Mar;40(3):032502
pubmed: 23464339
Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):970-988
pubmed: 29497803
Cancer Imaging. 2011 Jun 15;11:56-66
pubmed: 21684829
EJNMMI Phys. 2017 Dec;4(1):2
pubmed: 28063068
EJNMMI Phys. 2020 May 11;7(1):27
pubmed: 32394021
EJNMMI Phys. 2020 Feb 14;7(1):10
pubmed: 32060777
J Nucl Med. 1975 Apr;16(4):284-8
pubmed: 1113185
EJNMMI Phys. 2018 Jan 11;5(1):2
pubmed: 29322344